Search

Your search keyword '"Larrauri, Amparo"' showing total 14 results
Start Over Author "Larrauri, Amparo" Topic influenza vaccine
14 results on '"Larrauri, Amparo"'

1. 2015/16 I-MOVE/I-MOVE+ multicentre case-control study in Europe: Moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage-mismatched influenza B among children

Author

Kissling, Esther, Valenciano, Marta, Pozo, Francisco, Vilcu, Ana-Maria, Reuss, Annicka, Rizzo, Caterina, Larrauri, Amparo, Horváth, Judit Krisztina, Brytting, Mia, Domegan, Lisa, Korczyńska, Monika, Meijer, Adam, Machado, Ausenda, Ivanciuc, Alina, Višekruna Vučina, Vesna, van der Werf, Sylvie, Schweiger, Brunhilde, Bella, Antonino, Gherasim, Alin, Ferenczi, Annamária, Zakikhany, Katherina, O'Donnell, Joan, Paradowska-Stankiewicz, Iwona, Dijkstra, Frederika, Guiomar, Raquel, Lazar, Mihaela, Kurečić Filipović, Sanja, Johansen, Kari, Moren, Alain, I-MOVE/I-MOVE+ study team, EpiConcept [Paris], National Centre for Microbiology [Madrid], Instituto de Salud Carlos III [Madrid] (ISC), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Sorbonne Université (SU), Department for Infectious Disease Epidemiology [Berlin], Robert Koch Institute [Berlin] (RKI), Department of Infectious Diseases [Rome, Italy], Istituto Superiore di Sanita, CIBER de Epidemiología y Salud Pública (CIBERESP), National Centre for Epidemiology. CIBERNED. Carlos III Institute of Health, Madrid, Centro de Investigacion Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III [Madrid] (ISC)-Instituto de Salud Carlos III [Madrid] (ISC), National Centre for Epidemiology [Budapest], Public Health Agency of Sweden, Health Protection Surveillance Centre (HPSC), National Institute of Public Health - National Institute of Hygiene [Poland], National Institute for Public Health and the Environment [Bilthoven] (RIVM), Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), Cantacuzino Institute [Romania], Réseau International des Instituts Pasteur (RIIP), Croatian Institute of Public Health [Zagreb] (CIPH), Génétique moléculaire des virus à ARN ((U-Pasteur_ 2 / UMR_3569)), Institut Pasteur [Paris]-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), National Reference Centre for Influenza [Berlin], European Centre for Disease Prevention and Control (ECDC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Istituto Superiore di Sanità (ISS), Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses (GMV-ARN (UMR_3569 / U-Pasteur_2)), Institut Pasteur [Paris] (IP)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), European Centre for Disease Prevention and Control [Stockholm, Sweden] (ECDC), Instituto de Salud Carlos III (ISC), CIBER de Enfermedades Neurodegenerativas (CIBERNED), National Institute of Public Health – National Institute of Hygiene [Varsovie], Instituto Nacional de Saúde Doutor Ricardo Jorge [Lisboa], European Centre for Disease Prevention and Control, Kissling, Esther, Valenciano, Marta, Pozo, Francisco, Vilcu, Ana-Maria, Reuss, Annicka, Rizzo, Caterina, Larrauri, Amparo, Horváth, Judit Krisztina, Brytting, Mia, Domegan, Lisa, Korczyńska, Monika, Meijer, Adam, Machado, Ausenda, Ivanciuc, Alina, Višekruna Vučina, Vesna, van der Werf, Sylvie, Schweiger, Brunhilde, Bella, Antonino, Gherasim, Alin, Ferenczi, Annamária, Zakikhany, Katherina, O Donnell, Joan, Paradowska-Stankiewicz, Iwona, Dijkstra, Frederika, Guiomar, Raquel, Lazar, Mihaela, Kurečić Filipović, Sanja, Johansen, Kari, Moren, Alain, and D'Agaro, Pierlanfranco

Subjects
Male, 0301 basic medicine, Epidemiology, viruses, Influenza B viru, vaccine effectivene, Efetividade da Vacina Antigripal, Influenza A Virus, H1N1 Subtype, 0302 clinical medicine, Influenza A Virus, Medicine, 030212 general & internal medicine, Child, Vaccine effectiveness, I-MOVE+, virus diseases, Middle Aged, multicentre study, 3. Good health, Europe, Infectious Diseases, Influenza Vaccines, Child, Preschool, Original Article, Female, Case-Control Studie, influenza, Human, Adult, Pulmonary and Respiratory Medicine, Trivalent influenza vaccine, Lineage (genetic), Adolescent, Influenza vaccine, case-control study, 030106 microbiology, Influenza season, Young Adult, 03 medical and health sciences, Influenza, Human, Humans, I-MOVE, H1N1 Subtype, Vacina Antigripal, ddc:610, Preschool, Aged, vaccine effectiveness, case‐control study, business.industry, Cuidados de Saúde, Public Health, Environmental and Occupational Health, Case-control study, Infant, Influenza a, Original Articles, influenza vaccine, Case-Control Studies, Influenza B virus, Case Control Study, Virology, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, vaccine effe, [SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology, 610 Medizin und Gesundheit, business
Abstract

BACKGROUND: During the 2015/16 influenza season in Europe, the cocirculating influenza viruses were A(H1N1)pdm09 and B/Victoria, which was antigenically distinct from the B/Yamagata component in the trivalent influenza vaccine. METHODS: We used the test-negative design in a multicentre case-control study in twelve European countries to measure 2015/16 influenza vaccine effectiveness (VE) against medically attended influenza-like illness (ILI) laboratory-confirmed as influenza. General practitioners swabbed a systematic sample of consulting ILI patients and a random sample of influenza-positive swabs was sequenced. We calculated adjusted VE against influenza A(H1N1)pdm09, A(H1N1)pdm09 genetic group 6B.1 and influenza B overall and by age group. RESULTS: We included 11 430 ILI patients, of which 2272 were influenza A(H1N1)pdm09 and 2901 were influenza B cases. Overall VE against influenza A(H1N1)pdm09 was 32.9% (95% CI: 15.5-46.7). Among those aged 0-14, 15-64 and ≥65 years, VE against A(H1N1)pdm09 was 31.9% (95% CI: -32.3 to 65.0), 41.4% (95% CI: 20.5-56.7) and 13.2% (95% CI: -38.0 to 45.3), respectively. Overall VE against influenza A(H1N1)pdm09 genetic group 6B.1 was 32.8% (95% CI: -4.1 to 56.7). Among those aged 0-14, 15-64 and ≥65 years, VE against influenza B was -47.6% (95% CI: -124.9 to 3.1), 27.3% (95% CI: -4.6 to 49.4) and 9.3% (95% CI: -44.1 to 42.9), respectively. CONCLUSIONS: Vaccine effectiveness (VE) against influenza A(H1N1)pdm09 and its genetic group 6B.1 was moderate in children and adults, and low among individuals ≥65 years. Vaccine effectiveness (VE) against influenza B was low and heterogeneous among age groups. More information on effects of previous vaccination and previous infection is needed to understand the VE results against influenza B in the context of a mismatched vaccine. ECDC has contributed fund for the coordination and some study sites under the Framework contract no. ECDC/2014/026 for the individuals aged less than 65 years. The I‐MOVE/I‐MOVE+ study team is very grateful to all patients, general practitioners, paediatricians, hospital teams, laboratory teams and regional epidemiologists who have contributed to the study. We acknowledge the authors, originating and submitting laboratories of the sequences from GISAID's EpiFlu Database used for this study. All submitters of data may be contacted directly via the GISAID website http://www.gisaid.org. Sí

Published
2018

2. Interim 2019/20 influenza vaccine effectiveness: six European studies, September 2019 to January 2020

Author

Rose, Angela, Kissling, Esther, Emborg, Hanne-Dorthe, Larrauri, Amparo, McMenamin, Jim, Pozo, Francisco, Trebbien, Ramona, Mazagatos, Clara, Whitaker, Heather, Machado, Ausenda, Gómez, Verónica, Nunes, Baltazar, Kislaya, Irina, Pechirra, Pedro, Conde, Patrícia, Rodrigues, Ana Paula, Cristóvão, Paula, Costa, Inês, Guiomar, Raquel, and European IVE Group

Subjects
0301 basic medicine, Male, Infecções Respiratórias, Epidemiology, Observação e Vigilância, Gripe, Logistic regression, 0302 clinical medicine, Influenza A Virus, H1N1 Subtype, Interim, Outcome Assessment, Health Care, Medicine, 030212 general & internal medicine, Child, Vaccine effectiveness, Surveillance, Influenza vaccine, Vaccination, virus diseases, Middle Aged, multicentre study, Study Characteristics, Europe, Influenza Vaccines, Child, Preschool, Population Surveillance, Female, Seasons, Efectiveness, influenza, Test-negative design, Adolescent, 030106 microbiology, Influenza season, Primary care, Multicentre study, Sensitivity and Specificity, 03 medical and health sciences, Young Adult, Age groups, Virology, Influenza, Human, Humans, I-MOVE, EuroEVA, Aged, vaccine effectiveness, Portugal, business.industry, Influenza A Virus, H3N2 Subtype, test-negative design, Public Health, Environmental and Occupational Health, Efetividade, Influenza, Influenza B virus, Case-Control Studies, Immunization, Cuidados Saúde Primários, Determinantes da Saúde e da Doença, business, Demography
Abstract

Background Influenza A(H1N1)pdm09, A(H3N2) and B viruses were co-circulating in Europe between September 2019 and January 2020. Aim To provide interim 2019/20 influenza vaccine effectiveness (VE) estimates from six European studies, covering 10 countries and both primary care and hospital settings. Methods All studies used the test-negative design, although there were some differences in other study characteristics, e.g. patient selection, data sources, case definitions and included age groups. Overall and influenza (sub)type-specific VE was estimated for each study using logistic regression adjusted for potential confounders. Results There were 31,537 patients recruited across the six studies, of which 5,300 (17%) were cases with 5,310 infections. Most of these (4,466; 84%) were influenza A. The VE point estimates for all ages were 29% to 61% against any influenza in the primary care setting and 35% to 60% in hospitalised older adults (aged 65 years and over). The VE point estimates against A(H1N1)pdm09 (all ages, both settings) was 48% to 75%, and against A(H3N2) ranged from −58% to 57% (primary care) and −16% to 60% (hospital). Against influenza B, VE for all ages was 62% to 83% (primary care only). Conclusions Influenza vaccination is of continued benefit during the ongoing 2019/20 influenza season. Robust end-of-season VE estimates and genetic virus characterisation results may help understand the variability in influenza (sub)type-specific results across studies.

Published
2020

3. Effectiveness of Influenza Vaccine against Influenza A in Europe in Seasons of Different A(H1N1)Pdm09 and the Same A(H3N2) Vaccine Components (2016\textendash 17 and 2017\textendash 18)

Author

Kissling, Esther, Pozo, Francisco, Buda, Silke, Vilcu, Ana-Maria, Rizzo, Caterina, Gherasim, Alin, Horváth, Judit Krisztina, Brytting, Mia, Domegan, Lisa, Meijer, Adam, Paradowska-Stankiewicz, Iwona, Machado, Ausenda, Vučina, Vesna Višekruna, Lazar, Mihaela, Johansen, Kari, Dürrwald, Ralf, Werf, Sylvie, Bella, Antonino, Larrauri, Amparo, Ferenczi, Annamária, Zakikhany, Katherina, O'Donnell, Joan, Dijkstra, Frederika, Bogusz, Joanna, Guiomar, Raquel, Filipović, Sanja Kurečić, Pitigoi, Daniela, Penttinen, Pasi, Valenciano, Marta, EpiConcept [Paris], Instituto de Salud Carlos III [Madrid] (ISC), Robert Koch Institute [Berlin] (RKI), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Istituto Superiore di Sanità (ISS), CIBER de Epidemiología y Salud Pública (CIBERESP), Public Health Agency of Sweden, Health Protection Surveillance Centre (HPSC), National Institute for Public Health and the Environment [Bilthoven] (RIVM), National Institute of Public Health - National Institute of Hygiene [Poland], Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), Cantacuzino Institute [Romania], Réseau International des Instituts Pasteur (RIIP), European Centre for Disease Prevention and Control [Stockholm, Sweden] (ECDC), Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses (GMV-ARN (UMR_3569 / U-Pasteur_2)), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris] (CNR - laboratoire coordonnateur), Institut Pasteur [Paris] (IP), and University of Medicine and Pharmacy 'Carol Davila' Bucharest (UMPCD)

Subjects
Vaccine effectiveness, Europe, Influenza vaccine, Case-control study, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Multicentre study, [SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology, Influenza
Abstract

International audience; Introduction: Influenza A(H3N2) viruses predominated in Europe in 2016–17. In 2017–18 A(H3N2) and A(H1N1)pdm09 viruses co-circulated. The A(H3N2) vaccine component was the same in both seasons; while the A(H1N1)pdm09 component changed in 2017–18. In both seasons, vaccine seed A(H3N2) viruses developed adaptations/alterations during propagation in eggs, impacting antigenicity.Methods: We used the test-negative design in a multicentre primary care case-control study in 12 European countries to measure 2016–17 and 2017–18 influenza vaccine effectiveness (VE) against laboratory-confirmed influenza A(H1N1)pdm09 and A(H3N2) overall and by age group.Results: During the 2017–18 season, the overall VE against influenza A(H1N1)pdm09 was 59% (95% CI: 47–69). Among those aged 0–14, 15–64 and ≥65 years, VE against A(H1N1)pdm09 was 64% (95% CI: 37–79), 50% (95% CI: 28–66) and 66% (95% CI: 42–80), respectively. Overall VE against influenza A(H3N2) was 28% (95% CI: 17–38) in 2016–17 and 13% (95% CI: −15 to 34) in 2017–18. Among 0–14-year-olds VE against A(H3N2) was 28% (95%CI: −10 to 53) and 29% (95% CI: −87 to 73), among 15–64-year-olds 34% (95% CI: 18–46) and 33% (95% CI: −3 to 56) and among those aged ≥65 years 15% (95% CI: −10 to 34) and −9% (95% CI: −74 to 32) in 2016–17 and 2017–18, respectively.Conclusions: Our study suggests the new A(H1N1)pdm09 vaccine component conferred good protection against circulating strains, while VE against A(H3N2) was

Published
2019

4. 2015/16 to 2017/18 influenza seasons

Author

Machado, Ausenda, Mazagatos, Clara, Dijkstra, Frederika, Kislaya, Irina, Gherasim, Alin, McDonald, Scott A., Kissling, Esther, Valenciano, Marta, Meijer, Adam, Hooiveld, Mariëtte, Nunes, Baltazar, Larrauri, Amparo, Centro de Investigação em Saúde Pública (CISP/PHRC), and Escola Nacional de Saúde Pública (ENSP)

Subjects
averted cases, SDG 3 - Good Health and Well-being, Epidemiology, Virology, impact, Public Health, Environmental and Occupational Health, influenza vaccine, influenza
Abstract

BackgroundTo increase the acceptability of influenza vaccine, it is important to quantify the overall benefits of the vaccination programme.AimTo assess the impact of influenza vaccination in Portugal, Spain and the Netherlands, we estimated the number of medically attended influenza-confirmed cases (MAICC) in primary care averted in the seasons 2015/16 to 2017/18 among those ≥ 65 years.MethodsWe used an ecological approach to estimate vaccination impact. We compared the number of observed MAICC (n) to the estimated number that would have occurred without the vaccination programme (N). To estimate N, we used: (i) MAICC estimated from influenza surveillance systems, (ii) vaccine coverage, (iii) pooled (sub)type-specific influenza vaccine effectiveness estimates for seasons 2015/16 to 2017/18, weighted by the proportion of virus circulation in each season and country. We estimated the number of MAICC averted (NAE) and the prevented fraction (PF) by the vaccination programme.ResultsThe annual average of NAE in the population ≥ 65 years was 33, 58 and 204 MAICC per 100,000 in Portugal, Spain and the Netherlands, respectively. On average, influenza vaccination prevented 10.7%, 10.9% and 14.2% of potential influenza MAICC each season in these countries. The lowest PF was in 2016/17 (4.9-6.1%) with an NAE ranging from 24 to 69 per 100,000.ConclusionsOur results suggest that influenza vaccination programmes reduced a substantial number of MAICC. Together with studies on hospitalisations and deaths averted by influenza vaccination programmes, this will contribute to the evaluation of the impact of vaccination strategies and strengthen public health communication. publishersversion published

Published
2019

5. No effect modification of influenza virus vaccine effectiveness by age or chronic condition was observed in the 2010/11 to 2017/18 seasons.

Author

Machado, Ausenda, Leite, Andreia, Larrauri, Amparo, Gomez, Verónica, Rodrigues, Ana Paula, Kislaya, Irina, and Nunes, Baltazar

Abstract

Purpose Most European influenza vaccine strategies target individuals at higher risk of complications, which include, among others, individuals aged ≥65 years and with chronic conditions. These individuals not only have a high‐risk of post‐infection complications but also could have lower capacity of acquiring adequate vaccine‐induced protection. As such, chronic conditions and age could modify the effect of vaccines. This study aimed at assessing the potential effect modification of influenza vaccine effectiveness (IVE) by age and chronic conditions. Methods: We used eight‐season data from the Portuguese vaccine effectiveness study. Every season, physicians at primary care units recruited patients with influenza‐like illness. Clinical data and swabs were collected for Reverse Transverse Polymerase Chain Reaction (RT‐PCR) detection of influenza. Trivalent inactivated IVE was estimated as 1 – odds ratio (OR) of being vaccinated in cases (RT‐PCR positive for influenza) versus negative controls. ORs were obtained using a multivariable conditional logistic regression model, paired by week of onset within each season. Confounders were assessed by designing a specific causal diagram. Age (< 65 or ≥65 years) and chronic conditions (diabetes, cardiovascular disease, chronic renal disease, chronic hepatic disease, obesity, chronic respiratory disease, and congenital or acquired immunodeficiency) were studied as effect modifiers by including an interaction term in the regression models. Significance was established at 5%. Results: Point estimates indicate a higher IVE in the chronic condition strata compared to that in the no chronic condition strata. Regarding age, different results were obtained considering the virus type and (sub)type. When comparing the ≥65 years with the <65 years of age strata, we observed a higher IVE against A(H1N1)pdm09, an equal IVE against A(H3N2) and a lower IVE against B virus. However, all interaction terms were statistically insignificant, and this may be due to a small sample size. Conclusion: The potential effect modification of age or chronic condition was not observed within our study. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

6. Exploring the effect of previous inactivated influenza vaccination on seasonal influenza vaccine effectiveness against medically attended influenza: Results of the European I‐MOVE multicentre test‐negative case‐control study, 2011/2012‐2016/2017

Author

Valenciano, Marta, Kissling, Esther, Larrauri, Amparo, Nunes, Baltazar, Pitigoi, Daniela, O'Donnell, Joan, Reuss, Annicka, Horváth, Judit Krisztina, Paradowska-Stankiewicz, Iwona, Rizzo, Caterina, Falchi, Alessandra, Daviaud, Isabelle, Brytting, Mia, Meijer, Adam, Kaic, Bernard, Gherasim, Alin, Machado, Ausenda, Ivanciuc, Alina, Domegan, Lisa, Schweiger, Brunhilde, Ferenczi, Annamária, Korczyńska, Monika, Bella, Antonino, Vilcu, Ana-Maria, Mosnier, Anne, Zakikhany, Katherina, de Lange, Marit, Kurečić Filipovićović, Sanja, Johansen, Kari, and Moren, Alain

Subjects
vaccine effectiveness, case-control study, virus diseases, ddc:610, influenza vaccine, influenza, 610 Medizin und Gesundheit, multicentre study
Abstract

Background Results of previous influenza vaccination effects on current season influenza vaccine effectiveness (VE) are inconsistent. Objectives To explore previous influenza vaccination effects on current season VE among population targeted for vaccination. Methods We used 2011/2012 to 2016/2017 I‐MOVE primary care multicentre test‐negative data. For each season, we compared current season adjusted VE (aVE) between individuals vaccinated and unvaccinated in previous season. Using unvaccinated in both seasons as a reference, we then compared aVE between vaccinated in both seasons, current only, and previous only. Results We included 941, 2645 and 959 influenza‐like illness patients positive for influenza A(H1N1)pdm09, A(H3N2) and B, respectively, and 5532 controls. In 2011/2012, 2014/2015 and 2016/2017, A(H3N2) aVE point estimates among those vaccinated in previous season were −68%, −21% and −19%, respectively; among unvaccinated in previous season, these were 33%, 48% and 46%, respectively (aVE not computable for influenza A(H1N1)pdm09 and B). Compared to current season vaccination only, VE for both seasons' vaccination was (i) similar in two of four seasons for A(H3N2) (absolute difference [ad] 6% and 8%); (ii) lower in three of four seasons for influenza A(H1N1)pdm09 (ad 18%, 26% and 29%), in two seasons for influenza A(H3N2) (ad 27% and 39%) and in two of three seasons for influenza B (ad 26% and 37%); (iii) higher in one season for influenza A(H1N1)pdm09 (ad 20%) and influenza B (ad 24%). Conclusions We did not identify any pattern of previous influenza vaccination effect. Prospective cohort studies documenting influenza infections, vaccinations and vaccine types are needed to understand previous influenza vaccinations' effects.

Published
2018

7. Understanding influenza vaccination among Portuguese elderly: the social ecological framework.

Author

Machado, Ausenda, Santos, Ana João, Kislaya, Irina, Larrauri, Amparo, and Nunes, Baltazar

Subjects
ATTITUDE (Psychology), CONFIDENCE intervals, HEALTH behavior, HEALTH services accessibility, INFLUENZA vaccines, MEDICAL care use, QUESTIONNAIRES, SEX distribution, VACCINATION, IMMUNIZATION of older people, SEASONAL influenza, DATA analysis software, DESCRIPTIVE statistics, OLD age
Abstract

This study intended to identify and quantify the social ecological model (SEM) levels associated to seasonal IV uptake in the Portuguese elderly population. Data from the 2014 National Health Survey was restricted to individuals aged 65+ years (n = 5669). Twenty-three independent variables were allocated to the SEM levels: individual, interpersonal, organizational, community and policy. Sex stratified and age adjusted analysis using Poisson regression were performed for each level and for a fitted full model. Relative reduction in pseudo R magnitude measured marginal contribution of each level. For men and women, older groups (85+ vs. 65–69; men, PR = 1.59 and women, PR = 1.56); having 3+ chronic conditions (men, PR = 1.39 and women, PR = 1.35); previous 4 weeks GP and outpatient visits were associated to higher IV uptake. For men, only 2 SEM levels were associated (individual and organizational) while for women the community level was also relevant. Main marginal contribution came from individual (17.9% and 16.3%) and organizational (30.7% and 22.7%) levels. This study highlights the importance of individual characteristics, access and use of health care services for the IV uptake and the sex differential behaviour. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

8. Effect of previous and current vaccination against influenza A(H1N1)pdm09, A(H3N2), and B during the post-pandemic period 2010-2016 in Spain

Author

Gherasim, Alin Manuel, Martínez-Baz, Iván, Castilla, Jesús, Pozo Sanchez, Francisco, Larrauri, Amparo, cycEVA working group, Jimenez-Jorge, Silvia, Mateo-Ontañon, Salvador de, Delgado-Sanz, Concepcion, Oliva Dominguez, Jesus Angel, Savulescu, Camelia, Casas Flecha, Inmaculada, Garcia-Cenoz, Manuel, García-Cenoz, Manuel, European Commission, European Centre for Disease Prevention and Control (ECDC), Unión Europea. Comisión Europea, and European Centre for Disease Prevention and Control

Subjects
0301 basic medicine, RNA viruses, Male, Viral Diseases, Influenza Viruses, viruses, lcsh:Medicine, medicine.disease_cause, Pathology and Laboratory Medicine, Geographical Locations, 0302 clinical medicine, Influenza A Virus, H1N1 Subtype, Pandemic, Influenza A virus, Medicine and Health Sciences, Medicine, Public and Occupational Health, 030212 general & internal medicine, lcsh:Science, Child, Genetic Interference, Vaccines, Multidisciplinary, Viral Vaccine, virus diseases, Middle Aged, Vaccination and Immunization, 3. Good health, Vaccination, Europe, Infectious Diseases, Medical Microbiology, Influenza Vaccines, Viral Pathogens, Viruses, Physical Sciences, Female, Seasons, Pathogens, Statistics (Mathematics), Research Article, Adult, Infectious Disease Control, Adolescent, Influenza vaccine, 030106 microbiology, Immunology, Microbiology, Virus, 03 medical and health sciences, Young Adult, Virology, Influenza, Human, Genetics, Confidence Intervals, Humans, Microbial Pathogens, business.industry, Influenza A Virus, H3N2 Subtype, lcsh:R, Organisms, Biology and Life Sciences, Influenza a, Viral Vaccines, Confidence interval, Influenza, Influenza B virus, Spain, Case-Control Studies, People and Places, lcsh:Q, Preventive Medicine, business, Sentinel Surveillance, Mathematics, Orthomyxoviruses
Abstract

BACKGROUND: Recent studies suggest that the protective effect of the current influenza vaccine could be influenced by vaccination in previous seasons. We estimated the combined effect of the previous and current influenza vaccines from the 2010-2011 season to the 2015-2016 season in Spain. METHODS: We performed a test-negative case-control study in patients ≥9 years old. We estimated the influenza vaccine effectiveness (IVE) against influenza A(H1N1)pdm09, A(H3N2), and B virus. RESULTS: We included 1206 influenza A(H1N1)pdm09 cases, 1358 A(H3N2) cases and 1079 B cases. IVE against A(H1N1)pdm09 virus in the pooled-season analysis was 53% (95% Confidence Interval (CI): 21% to 72%) for those vaccinated only in the current season and 50% (95%CI: 23% to 68%) for those vaccinated in the both current and previous seasons. Against the influenza A(H3N2) virus, IVE was 17% (95%CI: -43% to 52%) for those vaccinated only in the current season and 3% (95%CI: -33% to 28%) for those vaccinated in both seasons. Regarding influenza B, we obtained similar IVEs for those vaccinated only in the current and those vaccinated in both seasons: 57% (95%CI: 12% to 79%) and 56% (95%CI: 36% to 70%), respectively. CONCLUSION: Our results suggested no interference between the previous and current influenza vaccines against A(H1N1)pdm09 and B viruses, but a possible negative interference against A(H3N2) virus. This study was funded by the Horizon 2020 program of the European Commission (I-MOVE-plus, EU 634446) and by the European Centre for Disease Prevention and Control (I-MOVE, ECDC tender OJ/16/07/2014-Proc/2014/024). Sí

Published
2017

9. Influenza pandemic (H1N1) 2009 activity during summer 2009: Effectiveness of the 2008-9 trivalent vaccine against pandemic influenza in Spain

Author

Larrauri, Amparo, Savulescu, Camelia, Jiménez-Jorge, Silvia, Pérez-Breña, Pilar, Pozo, Francisco, Casas, Inmaculada, Ledesma, Juan, and Mateo, Salvador de

Subjects
Adult, Male, Adolescent, Sentinel surveillance, Disease Outbreaks, Young Adult, Gripe humana, Influenza A Virus, H1N1 Subtype, Nasopharynx, Influenza, Human, Humans, Child, Aged, Vaccine effectiveness, Aged, 80 and over, Influenza vaccine, Incidence, Vaccination, Infant, Newborn, virus diseases, Infant, Efectividad vacunal, Middle Aged, Influenza Vaccines, Spain, Case-Control Studies, Child, Preschool, Population Surveillance, Carrier State, Vigilancia centinela, Human influenza, Female, Vacuna antigripal, Seasons
Abstract

Introduction: The Spanish influenza surveillance system (SISS) maintained its activity during the summer of 2009 to monitor the influenza pandemic. Objectives: To describe pandemic influenza activity from May to September 2009 and to estimate the effectiveness of the 2008-9 seasonal influenza vaccine against laboratory-confirmed pandemic (H1N1) 2009 influenza. Methods: Data from the SISS were used to identify the trend of pandemic (H1N1) 2009 influenza outside the influenza season. For the effectiveness study, we compared the vaccination status of notified cases [influenza-like illnesses (ILI) laboratory confirmed as pandemic influenza] with that of the test-negative controls. Results: The first laboratory-confirmed case of the pandemic virus was notified in the system in week 20/2009. The ILI rate increased gradually in the study period, exceeding basic activity in week 38. The proportion of pandemic (H1N1) 2009 influenza viruses detected by the system represented 14% in week 20/2009 and rapidly increased to 90% in week 34. The adjusted vaccine effectiveness of the 2008-9 seasonal vaccine against laboratory-confirmed pandemic influenza was 12% (-30; 41). Conclusions: The SISS became an essential tool for pandemic monitoring in Spain. The improved SISS will provide more accurate information on influenza activity in future seasonal or pandemic waves. Using surveillance data, we could not demonstrate the effectiveness of the seasonal 2008-9 vaccine against laboratory-confirmed pandemic influenza. Introducción: El Sistema de Vigilancia de Gripe en España (SVGE) continuó y reforzó su actividad durante el verano de 2009 con el objetivo de vigilar la evolución de la pandemia en España. Objetivos: Describir la actividad de la gripe pandémica en España de mayo a septiembre de 2009 y estimar la efectividad de la vacuna antigripal estacional 2008-2009 frente a casos confirmados de gripe pandémica (H1N1) 2009. Métodos: Se utilizaron datos del SVGE para presentar la evolución de la pandemia por virus (H1N1) 2009 fuera de la temporada de vigilancia 2008-2009. Para el estudio de la efectividad vacunal se comparó el estado vacunal de los casos de gripe pandémica confirmados por laboratorio con el de los casos negativos para el virus de la gripe (controles negativos). Resultados: El primer caso confirmado de virus pandémico se notificó en la semana 20/2009. La incidencia de gripe aumentó paulatinamente durante el periodo estudiado y sobrepasó el umbral basal en la semana 38/2009. La proporción de virus (H1N1) 2009 detectada por el SVGE fue del 14% en la semana 20 y aumentó rápidamente, llegando a alcanzar el 90% en la semana 34. La efectividad ajustada de la vacuna antigripal 2008-2009 frente a casos confirmados de gripe pandémica fue del 12% (-30; 41). Conclusiones: El SVGE se adaptó y mejoró de forma rápida a las exigencias nacionales e internacionales de vigilancia de la pandemia. Esta mejora supone información más precisa y de calidad en futuras ondas epidémicas/pandémicas. Con los datos obtenidos en vigilancia no se pudo demostrar alguna efectividad de la vacuna antigripal 2008-2009 frente a los casos de gripe pandémica confirmados por laboratorio.

Published
2011

10. Exploring the effect of clinical case definitions on influenza vaccine effectiveness estimation at primary care level: Results from the end-of-season 2022–23 VEBIS multicentre study in Europe.

Author

Maurel, Marine, Mazagatos, Clara, Goerlitz, Luise, Oroszi, Beatrix, Hooiveld, Mariette, Machado, Ausenda, Domegan, Lisa, Ilić, Maja, Popescu, Rodica, Sève, Noémie, Martínez-Baz, Iván, Larrauri, Amparo, Buda, Silke, Túri, Gergő, Meijer, Adam, Gomez, Verónica, O'Donnell, Joan, Mlinarić, Ivan, Timnea, Olivia, and Diez, Ana Ordax

Subjects
*FLU vaccine efficacy, *PRIMARY care, *PATIENT selection, *INFLUENZA vaccines, *DEFINITIONS
Abstract

Within influenza vaccine effectiveness (VE) studies at primary care level with a laboratory-confirmed outcome, clinical case definitions for recruitment of patients can vary. We used the 2022–23 VEBIS primary care European multicentre study end-of-season data to evaluate whether the clinical case definition affected IVE estimates. We estimated VE using a multicentre test-negative case-control design. We measured VE against any influenza and influenza (sub)types, by age group (0–14, 15–64, ≥65 years) and by influenza vaccine target group, using logistic regression. We estimated IVE among patients meeting the European Union (EU) acute respiratory infection (ARI) case definition and among those meeting the EU influenza-like illness (ILI) case definition, including only sites providing information on specific symptoms and recruiting patients using an ARI case definition (as the EU ILI case definition is a subset of the EU ARI one). We included 24 319 patients meeting the EU ARI case definition, of whom 21 804 patients (90 %) meet the EU ILI case definition, for the overall pooled VE analysis against any influenza. The overall and influenza (sub)type-specific VE varied by ≤2 % between EU ILI and EU ARI populations. Among all analyses, we found similar VE estimates between the EU ILI and EU ARI populations, with few (10%) additional non-ILI ARI patients recruited. These results indicate that VE in the 2022–23 influenza season was not affected by use of a different clinical case definition for recruitment, although we recommend investigating whether this holds true for next seasons. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Effectiveness of influenza vaccine against influenza A in Europe in seasons of different A(H1N1)pdm09 and the same A(H3N2) vaccine components (2016–17 and 2017–18)

Author

Kissling, Esther, Pozo, Francisco, Buda, Silke, Vilcu, Ana-Maria, Rizzo, Caterina, Gherasim, Alin, Horváth, Judit Krisztina, Brytting, Mia, Domegan, Lisa, Meijer, Adam, Paradowska-Stankiewicz, Iwona, Machado, Ausenda, Višekruna Vučina, Vesna, Lazar, Mihaela, Johansen, Kari, Dürrwald, Ralf, Van Der Werf, Sylvie, Bella, Antonino, Larrauri, Amparo, Ferenczi, Annamária, Zakikhany, Katherina, O'Donnell, Joan, Dijkstra, Frederika, Bogusz, Joanna, Guiomar, Raquel, Kurečić Filipović, Sanja, Pitigoi, Daniela, Penttinen, Pasi, Valenciano, Marta, and I-MOVE/I-MOVE+ Study Team

Subjects
Vaccine effectiveness, Europe, Influenza vaccine, Case-control study, 610 Medizin und Gesundheit, Influenza, multicentre study, 3. Good health
Abstract

Introduction Influenza A(H3N2) viruses predominated in Europe in 2016–17. In 2017–18 A(H3N2) and A(H1N1)pdm09 viruses co-circulated. The A(H3N2) vaccine component was the same in both seasons; while the A(H1N1)pdm09 component changed in 2017–18. In both seasons, vaccine seed A(H3N2) viruses developed adaptations/alterations during propagation in eggs, impacting antigenicity. Methods We used the test-negative design in a multicentre primary care case-control study in 12 European countries to measure 2016–17 and 2017–18 influenza vaccine effectiveness (VE) against laboratory-confirmed influenza A(H1N1)pdm09 and A(H3N2) overall and by age group. Results During the 2017–18 season, the overall VE against influenza A(H1N1)pdm09 was 59% (95% CI: 47–69). Among those aged 0–14, 15–64 and ≥65 years, VE against A(H1N1)pdm09 was 64% (95% CI: 37–79), 50% (95% CI: 28–66) and 66% (95% CI: 42–80), respectively. Overall VE against influenza A(H3N2) was 28% (95% CI: 17–38) in 2016–17 and 13% (95% CI: −15 to 34) in 2017–18. Among 0–14-year-olds VE against A(H3N2) was 28% (95%CI: −10 to 53) and 29% (95% CI: −87 to 73), among 15–64-year-olds 34% (95% CI: 18–46) and 33% (95% CI: −3 to 56) and among those aged ≥65 years 15% (95% CI: −10 to 34) and −9% (95% CI: −74 to 32) in 2016–17 and 2017–18, respectively. Conclusions Our study suggests the new A(H1N1)pdm09 vaccine component conferred good protection against circulating strains, while VE against A(H3N2) was

12. 2015/16 I‐MOVE/I‐MOVE+ multicentre case‐control study in Europe: Moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage‐mismatched influenza B among children

Author

Kissling, Esther, Valenciano, Marta, Pozo, Francisco, Vilcu, Ana-Maria, Reuss, Annicka, Rizzo, Caterina, Larrauri, Amparo, Horváth, Judit Krisztina, Brytting, Mia, Domegan, Lisa, Korczyńska, Monika, Meijer, Adam, Machado, Ausenda, Ivanciuc, Alina, Višekruna Vučina, Vesna, Van Der Werf, Sylvie, Schweiger, Brunhilde, Bella, Antonino, Gherasim, Alin, Ferenczi, Annamária, Zakikhany, Katherina, O'Donnell, Joan, Paradowska-Stankiewicz, Iwona, Dijkstra, Frederika, Guiomar, Raquel, Lazar, Mihaela, Kurečić Filipović, Sanja, Johansen, Kari, Moren, Alain, and I-MOVE/I-MOVE+ Study Team

Subjects
case-control study, virus diseases, vaccine effe, influenza vaccine, influenza, 610 Medizin und Gesundheit, multicentre study, 3. Good health
Abstract

Background During the 2015/16 influenza season in Europe, the cocirculating influenza viruses were A(H1N1)pdm09 and B/Victoria, which was antigenically distinct from the B/Yamagata component in the trivalent influenza vaccine. Methods We used the test‐negative design in a multicentre case‐control study in twelve European countries to measure 2015/16 influenza vaccine effectiveness (VE) against medically attended influenza‐like illness (ILI) laboratory‐confirmed as influenza. General practitioners swabbed a systematic sample of consulting ILI patients and a random sample of influenza‐positive swabs was sequenced. We calculated adjusted VE against influenza A(H1N1)pdm09, A(H1N1)pdm09 genetic group 6B.1 and influenza B overall and by age group. Results We included 11 430 ILI patients, of which 2272 were influenza A(H1N1)pdm09 and 2901 were influenza B cases. Overall VE against influenza A(H1N1)pdm09 was 32.9% (95% CI: 15.5‐46.7). Among those aged 0‐14, 15‐64 and ≥65 years, VE against A(H1N1)pdm09 was 31.9% (95% CI: −32.3 to 65.0), 41.4% (95% CI: 20.5‐56.7) and 13.2% (95% CI: −38.0 to 45.3), respectively. Overall VE against influenza A(H1N1)pdm09 genetic group 6B.1 was 32.8% (95% CI: −4.1 to 56.7). Among those aged 0‐14, 15‐64 and ≥65 years, VE against influenza B was −47.6% (95% CI: −124.9 to 3.1), 27.3% (95% CI: −4.6 to 49.4) and 9.3% (95% CI: −44.1 to 42.9), respectively. Conclusions Vaccine effectiveness (VE) against influenza A(H1N1)pdm09 and its genetic group 6B.1 was moderate in children and adults, and low among individuals ≥65 years. Vaccine effectiveness (VE) against influenza B was low and heterogeneous among age groups. More information on effects of previous vaccination and previous infection is needed to understand the VE results against influenza B in the context of a mismatched vaccine.

13. Waning protection of influenza vaccine against mild laboratory confirmed influenza A(H3N2) and B in Spain, season 2014–15.

Author

Gherasim, Alin, Pozo, Francisco, de Mateo, Salvador, Aspiritxaga Gamarra, Inma, García-Cenoz, Manuel, Vega, Tomas, Martínez, Eva, Giménez, Jaume, Castrillejo, Daniel, and Larrauri, Amparo

Subjects
*INFLUENZA A virus, H3N2 subtype, *VACCINATION, *VACCINE effectiveness, *IMMUNE response, *SCIENTIFIC observation
Abstract

Introduction The 2014/15 influenza season in Spain was dominated by the circulation of drifted A(H3N2) and co-circulation of B viruses. We present the final estimates of influenza vaccine effectiveness (IVE) against confirmed influenza A(H3N2) and B its evolution along the season and with time since vaccination. Methods We used data collected on influenza like illness patients (ILI), systematically swabbed for the presence of influenza viruses within the Spanish Influenza Sentinel Surveillance System (SISS) and a restricted observational study (cycEVA). We used a test negative case–control design to compare influenza confirmed cases with negative controls. We estimated the IVE through a logistic regression model adjusting for potential confounders. The evolution of IVE was studied in early and late stages of the epidemic, and in different time intervals between receiving influenza vaccination and the onset of symptoms. Results At the end of the season we have found low and moderate IVE point estimates against influenza A(H3N2) and B, respectively, in all ages and target groups for vaccination. An IVE decreased from an early value of 37% to a late of −76% against influenza A(H3N2), and similarly, 84% vs −4% against Influenza B. When the onset of symptoms occurred more than three months after vaccination, the decrease of IVE was slower and milder against influenza B than against influenza A(H3N2). No significant change in the percentage of circulating drifted influenza A(H3N2) strains belonging to the 3c.2a and 3c.3a clades could be identified through the season. Conclusions In a season dominated by drifted A(H3N2) circulating virus, the vaccine offered little or no protection against A(H3N2) infection but had a moderate protective effect against influenza B. Efforts should be put in developing influenza vaccines that maintain their protective capabilities throughout the season and could stimulate a potentially broad immune response against diverse influenza strains. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

14. Estimating the influenza vaccine effectiveness in elderly on a yearly basis using the Spanish influenza surveillance network—Pilot case–control studies using different control groups, 2008–2009 season, Spain

Author

Savulescu, Camelia, Valenciano, Marta, de Mateo, Salvador, and Larrauri, Amparo

Subjects
*INFLUENZA vaccines, *TREATMENT effectiveness, *IMMUNIZATION of older people, *PUBLIC health surveillance, *CASE-control method, *CONTROL groups, *INFLUENZA prevention
Abstract

Abstract: We conducted a case–control and screening method studies to estimate influenza vaccine effectiveness (IVE) in the age group ≥65 years, based on the Spanish Influenza Sentinel Surveillance System (SISSS). Cases (influenza laboratory-confirmed) were compared to influenza-negative ILI patients (test-negative) and patients without ILI since the beginning of the season (non-ILI). For the screening method, cases’ vaccination coverage was compared to the vaccination coverage of the GPs’ catchment population. The results suggested a protective effect of the vaccine against laboratory-confirmed influenza in elderly in 2008–2009. The screening method and the test-negative control designs enable estimating IVE using exclusively SISSS data. [Copyright &y& Elsevier]

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results